Advertisement

Topics

Global Sexual Health Partnering 20102017: Deal trends, players and financials [Updated: 01022017] Prices from USD $2995

21:33 EST 25 Feb 2017 | BioPortfolio Reports

Global Sexual Health Partnering 2010 to 2017 provides the full collection of Sexual Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

Trends in Sexual Health partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Sexual Health partnering agreement structure
Sexual Health partnering contract documents
Top Sexual Health deals by value
Most active Sexual Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multicomponent including both a collaborative RD and a commercialization of outcomes element.

The report takes readers through the comprehensive Sexual Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Sexual Health deals.

The report presents financial deal terms values for Sexual Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Sexual Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Sexual Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Sexual Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Sexual Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Sexual Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Sexual Health partnering deals by specific Sexual Health target announced since 2010. The chapter is organized by specific Sexual Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Sexual Health partnering deals signed and announced since 2010. The appendices are organized by company AZ, stage of development at signing, deal type collaborative RD, copromotion, licensing etc and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Sexual Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Sexual Health technologies and products.

Report scope

Global Sexual Health Partnering 2010 to 2017 is intended to provide the reader with an indepth understanding and access to Sexual Health trends and structure of deals entered into by leading companies worldwide.

Global Sexual Health Partnering 2010 to 2017 includes:

Trends in Sexual Health dealmaking in the biopharma industry since 2010
Analysis of Sexual Health deal structure
Access to headline, upfront, milestone and royalty data
Access to hundreds of Sexual Health deal contract documents
Comprehensive access to over 3500 Sexual Health deal records
The leading Sexual Health deals by value since 2010
Most active Sexual Health dealmakers since 2010

The report includes deals for the following indications: Bacterial vaginosis, Candida albicans Thrush, Contraception, Erectile dysfunction, Sexual dysfunction, Sexually transmitted disease STI, Chlamydia, Genital warts, Gonorrhea, Herpes, Syphilis, Trichomoniasis, plus other sexual health indications.

In Global Sexual Health Partnering 2010 to 2017, available deals and contracts are listed by:

Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Sexual Health Partnering 20102017 report provides comprehensive access to available deals and contract documents for over 100 sexual health deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Original Article: Global Sexual Health Partnering 20102017: Deal trends, players and financials [Updated: 01022017] Prices from USD $2995

NEXT ARTICLE

More From BioPortfolio on "Global Sexual Health Partnering 20102017: Deal trends, players and financials [Updated: 01022017] Prices from USD $2995"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Sexual Health
The World Health Organization (WHO) definition of sexual health; "the state of physical, emotional, mental and social well-being related to sexuality; it is not merely the absence of disease, dysfunction and infirmity. Sexual health requires a posit...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...